<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30275562</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1476-5594</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Oncogene</Title>                <ISOAbbreviation>Oncogene</ISOAbbreviation>            </Journal>            <ArticleTitle>XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41388-018-0513-8</ELocationID>            <Abstract>                <AbstractText>X-linked inhibitor of apoptosis protein (XIAP) possesses a critical role in promotion of cell survival and maintenance of cellular homeostasis. In cancer, elevated XIAP expression has been associated with malignancy, poor prognosis, and treatment resistance. However, the underlying mechanisms of these effects remain unclear. XIAP has previously been proposed to promote tumor growth through suppression of autophagy. In this study, we examined the expression of XIAP and p62, two critical mediators of autophagy, in breast and colon cancer. We observed a negative correlation between XIAP and p62 expression in normal and cancer tissues of breast and colon, and that the ratio of XIAP and p62 expression determines the cancer phenotype. In vitro, we observed that XIAP interacted with p62 and also that XIAP depletion resulted in increased expression of p62. XIAP functioned as an ubiquitination E3 ligase towards p62 and suppressed p62 expression through ubiquitin-proteasomal degradation. Furthermore, XIAP enhanced cancer cell proliferation, viability, and colony formation in vitro via suppression of p62. In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo. Herein, we have therefore delineated a novel mechanism by which XIAP contributes to development and progression of breast and colon carcinoma.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Xing</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, Zhejiang, China. dr.huangxing@foxmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Developmental Genes and Human Disease, Institute of Life Sciences, Southeast University, 210096, Nanjing, Jiangsu, China. dr.huangxing@foxmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xiao-Nan</ForeName>                    <Initials>XN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Anhui Medical University, 230032, Hefei, Anhui, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Xiao-Dong</ForeName>                    <Initials>XD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Anhui Medical University, 230032, Hefei, Anhui, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Wen-Yong</ForeName>                    <Initials>WY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, 230032, Hefei, Anhui, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lobie</LastName>                    <ForeName>Peter E</ForeName>                    <Initials>PE</Initials>                    <AffiliationInfo>                        <Affiliation>Tsinghua Berkeley Shenzhen Institute, Tsinghua University, Shenzhen, Guangdong, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Zhengsheng</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Anhui Medical University, 230032, Hefei, Anhui, China. woozson@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Oncogene</MedlineTA>            <NlmUniqueID>8711562</NlmUniqueID>            <ISSNLinking>0950-9232</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30275562</ArticleId>            <ArticleId IdType="doi">10.1038/s41388-018-0513-8</ArticleId>            <ArticleId IdType="pii">10.1038/s41388-018-0513-8</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>